Rocket Pharmaceuticals won an FDA approval for Kresladi, a gene therapy for leukocyte-adhesion deficiency type 1 (LAD-1), an ultra-rare inherited immunodeficiency that can be fatal in infancy. The approval makes Kresladi the first commercial gene therapy product for Rocket and the first gene therapy indicated for LAD-1. For biopharma stakeholders, the decision adds another anchor label to the growing commercial gene therapy category, while reinforcing FDA’s willingness to support ultra-rare programs with focused evidentiary packages. Rocket’s positioning also highlights the sector’s continued shift toward single-gene causes and targeted correction approaches in early life disorders. The next phase for Rocket will center on scaling access and managing real-world safety and durability expectations as patients are treated outside the initial trial footprint. Payers and treatment centers will also weigh administration infrastructure and follow-up needs as gene therapies become routine clinical products.